查詢結果分析
來源資料
相關文獻
- 桃仁承氣湯及三黃瀉心湯併用aspirin治療缺血後腦中風及降低神經行為缺陷之交互作用與引起胃出血、顱內出血和蜘蛛膜下腔出血之風險評估
- 桃仁承氣湯及三黃瀉心湯併用aspirin治療缺血後腦中風及降低神經行為缺陷之交互作用與引起胃出血、顱內出血和蜘蛛膜下腔出血之風險評估
- 以動脈注射血栓溶劑治療急性缺血性腦中風:七例報告
- 成功使用血栓溶解劑治療急性缺血性腦中風:一病例報告暨文獻回顧
- Cranial Computed Tomography in Ischemic Stroke Patients with and without Dementia--A Prospective Study
- 缺血性腦中風的治療
- Common Carotid Artery Thrombosis Causing Ischemic Stroke in a Patient with Systemic Lupus Erythematosus
- 使用血栓溶解劑治療急性缺血性腦中風--病例報告
- 頭部CT不見病變之急性缺血性腦中風--兼論腦缺血之急性誘因及治療
- 應用中文化中風量表評估急性缺血性腦中風患者可信度之研究
頁籤選單縮合
題 名 | 桃仁承氣湯及三黃瀉心湯併用aspirin治療缺血後腦中風及降低神經行為缺陷之交互作用與引起胃出血、顱內出血和蜘蛛膜下腔出血之風險評估=Comparative Studies of Tao-Ren-Cheng-Qi Tang or San-Huang-Xie-Xin Tang with Aspirin on Neuroprotection and Lowering the Neurobehavioral Deficits in Rat Ischemic Stroke: Evaluation the Risks of Inducing Gastric Bleeding, Intracerebral Hemorrhage, and Subarachnoid Hemorrhage |
---|---|
編 次 | (2-2) |
作 者 | 許準榕; | 書刊名 | 中醫藥年報 |
卷 期 | 3 2014.12[民103.12] |
頁 次 | 頁(83)1-(83)34 |
分類號 | 414.5 |
關鍵詞 | 桃仁承氣湯; 三黃瀉心湯; 缺血性腦中風; 出血性副作用; Aspirin; Ischemic stroke; TRCQT; SHXXT; Hemorrhage; Side effect; |
語 文 | 中文(Chinese) |
中文摘要 | 腦中風是血管性疾病致死及發病的主要原因之ㄧ,影響人類健康甚鉅。中醫在腦中風的治療上,常用桃仁承氣湯及三黃瀉心湯做為臨床方劑;另一方面,西醫臨床上常用抗血小板藥物,如 aspirin來治療中風。目前台灣有許多患者常會同時併用傳統中藥方劑與西藥如 aspirin來治療或預防腦血管疾病,因此了解其相關的交互作用與副作用是值得深入研究的重要課題。本計畫利用自體凝血塊引起中腦動脈阻塞的腦中風模式,來評估桃仁承氣湯和三黃瀉心湯,分別併用不同劑量 aspirin下,其治療缺血後腦中風與降低因腦中風所引起之神經行為缺陷的交互作用,是否會引起出血的風險評估及同時探討其可能作用機制。在去年度計畫中,我們證明了桃仁承氣湯( 0.5及 0.25克/公斤/天)對於缺血性中風後腦部傷害,具有明顯的療效。今年度的計畫中,我們探討桃仁承氣湯和三黃瀉心湯,分別併用不同劑量 aspirin下,是否會引起出血的風險評估及同時探討其可能作用機制。實驗結果顯示,不論是單獨餵食桃仁承氣湯 (TRCQT)(0.5克/公斤/天)、三黃瀉心湯(SHXXT)(0.2克/公斤/天)或 aspirin(5毫克 /公斤/天),或者併用中藥方劑與 aspirin,在 1、2及 3個月後對於腦組織中血紅蛋白含量、胃液中血紅蛋白含量、蜘蛛膜下腔血塊形成、凝血酶原時間,都沒有具統計意義的影響,因而沒有出血性副作用。除此之外,三黃瀉心湯能夠顯著抑制胃液中血紅蛋白含量,而桃仁承氣湯相對於三黃瀉心湯,能夠顯著的延長小鼠斷尾凝血時間以及抑制血小板凝集。因此我們認為在本研究之劑量下,三黃瀉心湯可能具有止血的效果來防止藥物造成的出血性副作用產生;而桃仁承氣湯併用 aspirin治療能夠藉抑制中風後腦內微小血栓的凝集而治療中風,且不會有出血性副作用。 |
英文摘要 | Stroke is the third leading cause of mortality and morbidity in the world. Tao-Ren-Cheng-Qi Tang (TRCQT) and San-Huang-Xie-Xin Tang (SHXXT), traditional Chinese medicines (TCM), have long been used by traditional Chinese physicians to treat ischemic stroke in China. On the other hand, aspirin are routinely used to prevent ischemic stroke clinically. Nevertheless, many studies indicate that taking aspirin will increase the risk of excessive bleeding and vascular diseases. In Taiwan, a large number of patients often use TCM and aspirin simultaneously to treat or prevent cerebrovascular diseases. Therefore, investigation of the interactions and possible risks of these drugs combination is important and warrant study. A combination of two doses of TRCQT or SHXXT with aspirin was used in this project to investigate their interactions and risks during the autologous blood clot-induced ischemic stroke and neurobehavioral deficits in rats. In addition, this project also studied the effect of these TCM on bleeding risk and explores the possible mechanisms. Our earlier study shown that TRCQT (0.25 and 0.5 g/kg) reduced middle cerebral artery occlusion (MCAO)-induced brain injury, but SHXXT had no effect. The results of this project demonstrated that treatment of TRCQT (0.5 g/kg/day) and SHXXT (0.2 g/kg/day) alone or combined with or without aspirin (5 mg/kg/day) in rats after MCAO for 1,2 or 3 months had no hemorrhage side effect such as subarachnoid hemorrhage, gastric bleeding, cerebral hemorrhage and prolonged prothrombin time. In addition, TRCQT (0.5 g/kg/day) significantly extended the tail bleeding time and shown anti-platelet aggregation effect. Moreover, SHXXT (0.2 g/kg/day) decreases the gastric bleeding in MCAO-induced rats. In conclusion, the present results reveal the evidence that TRCQT and SHXXT possess beneficial protection against MCAO-induced neurotoxicity in rats without causing any hemorrhagic side effects. Hence, these TCMs can be used as potentially alternative and complementary medicine for neuroprotection. |
本系統中英文摘要資訊取自各篇刊載內容。